Prognostic and diagnostic value of des-γ-carboxy prothrombin in liver cancer

Drug News and Perspectives

Volumn 23, Issue 8, 2010, Pages 498-508

  Bertino, Gaetano ^a   Ardiri, Annalisa Maria ^a   Calvagno, Giuseppe Stefano ^a   Bertino, Nicoletta ^b   Boemi, Patrizia Maria ^a  

^a UNIVERSITY OF CATANIA   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

DECARBOXYPROTHROMBIN; VASCULOTROPIN; ALPHA FETOPROTEIN; BIOLOGICAL MARKER; PROTEIN PRECURSOR; PROTHROMBIN; TUMOR MARKER;

CANCER DIAGNOSIS; CANCER INVASION; CANCER RECURRENCE; CANCER STAGING; CELL MIGRATION; DIAGNOSTIC VALUE; DISEASE MARKER; HEPATITIS B; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; REVIEW; ANIMAL; BLOOD; LIVER TUMOR; METABOLISM; METASTASIS; PATHOLOGY; PROGNOSIS; SENSITIVITY AND SPECIFICITY; TUMOR RECURRENCE;

ALPHA-FETOPROTEINS; ANIMALS; BIOLOGICAL MARKERS; CARCINOMA, HEPATOCELLULAR; HUMANS; LIVER NEOPLASMS; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROTEIN PRECURSORS; PROTHROMBIN; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 79952284046     PISSN: 02140934     EISSN: None     Source Type: Journal    
DOI: 10.1358/dnp.2010.23.8.1444236     Document Type: Review

References (95)

1. El-Serag, H.B., Rudolph, K.L. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007, 132(7): 2557-76. (Pubitemid 46890874)
2. Parkin, D.M. Global cancer statistics in the year 2000. Lancet Oncol 2001, 2(9): 533-43.
3. McGlynn, K.A., Tsao, L., Hsing, A.W., Devesa, S.S., Fraumeni, J.F., Jr. International trends and patterns of primary liver cancer. Int J Cancer 2001, 94(2): 290-6. (Pubitemid 32911426)
4. Kirk, G.D., Lesi, O.A., Mendy, M. et al. The Gambia Liver Cancer Study: Infection with hepatitis B and C and the risk of hepatocellular carcinoma in West Africa. Hepatology 2004, 39(1): 211-9. (Pubitemid 38461484)
5. Umemura, T., Kiyosawa, K. Epidemiology of hepatocellular carcinoma in Japan. Hepatol Res 2007, 37(Suppl 2): S95-S100.
6. El-Serag, H.B., Mason, A.C. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999, 340(10): 745-50. (Pubitemid 29114292)
7. Okuda, K. Hepatocellular carcinoma. J Hepatol 2000, 32(1 Suppl): 225-37. (Pubitemid 30123637)
8. Bruix, J., Sherman, M., Llovet, J.M. et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001, 35(3): 421-30. (Pubitemid 32844200)
9. Befeler, A.S., Di Bisceglie, A.M. Hepatocellular carcinoma: diagnosis and treatment. Gastroenterology 2002, 122(6): 1609-19. (Pubitemid 34533556)
10. Llovet, J.M., Burroughs, A., Bruix, J. Hepatocellular carcinoma. Lancet 2003, 362(9399): 1907-17. (Pubitemid 37518510)
11. Llovet, J.M., Fuster, J., Bruix, J. The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma. Liver Transpl 2004, 10(2 Suppl 1): S115-20.
12. Kiyosawa, K., Umemura, T., Ichijo, T., Matsumoto, A., Yoshizawa, K., Gad, A., Tanaka, E. Hepatocellular carcinoma: recent trends in Japan. Gastroenterology 2004, 127(5 Suppl 1): S17-26.
13. El-Serag, H.B. Hepatocellular carcinoma: recent trends in the United States. Gastroenterology 2004, 127(5 Suppl 1): S27-34.
14. Fattovich, G., Stroffolini, T., Zagni, I., Donato, F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004, 127(5 Suppl 1): S35-50.
15. Blum, H.E. Hepatocellular carcinoma: therapy and prevention. World J Gastroenterol 2005, 11(47): 7391-400. (Pubitemid 43126017)
16. Di Bisceglie, A.M. Screening for hepatocellular carcinoma: being old is not all bad. Am J Gastroenterol 2004, 99(8): 1477-8. (Pubitemid 39180094)
17. Talwalkar, J.A., Gores, G.J. Diagnosis and staging of hepatocellular carcinoma. Gastroenterology 2004, 127(5 Suppl 1): S126-32.
18. Spangenberg, H.C., Thimme, R., Blum, H.E. Serum markers of hepatocellular carcinoma. Semin Liver Dis 2006, 26(4): 385-90. (Pubitemid 44632929)
19. Volk, M.L., Hernandez, J.C., Su, G.L., Lok, A.S., Marrero, J.A. Risk factors for hepatocellular carcinoma may impair the performance of biomarkers: a comparison of AFP, DCP, and AFPL3. Cancer Biomark 2007, 3(2): 79-87. (Pubitemid 47103809)
20. Pontisso, P., Quarta, S., Caberlotto, C. et al. Progressive increase of SCCA-IgM immune complexes in cirrhotic patients is associated with development of hepatocellular carcinoma. Int J Cancer 2006, 119(4): 735-40. (Pubitemid 44051434)
21. Weitz, I.C., Liebman, H.A. Des-gamma-carboxy (abnormal) prothrombin and hepatocellular carcinoma: a critical review. Hepatology 1993, 18(4): 990-7.
22. Marrero, J.A., Su, G.L., Wei, W., Emick, D., Conjeevaram, H.S., Fontana, R.J., Lok, A.S. Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in American patients. Hepatology 2003, 37(5): 1114-21.
23. Marrero, J.A., Lok, A.S. Newer markers for hepatocellular carcinoma. Gastroenterology 2004, 127(5 Suppl 1): S113-9.
24. Grizzi, F., Franceschini, B., Hamrick, C., Frezza, E.E., Cobos, E., Chiriva-Internati, M. Usefulness of cancer-testis antigens as biomarkers for the diagnosis and treatment of hepatocellular carcinoma. J Transl Med 2007, 5: 3.
25. Ueda, N., Shiraha, H., Fujikawa, T. et al. Exon 2 deletion splice variant of gamma-glutamyl carboxylase causes des-gamma-carboxy prothrombin production in hepatocellular carcinoma cell lines. Mol Oncol 2008, 2(3): 241-9.
26. Wright, L.M., Kreikemeier, J.T., Fimmel, C.J. A concise review of serum markers for hepatocellular cancer. Cancer Detect Prev 2007, 31(1): 35-44. (Pubitemid 46367447)
27. Bertino, G., Ardiri, A.M., Boemi, P.M. et al. A study about mechanisms of des-gamma-carboxy prothrombin's production in hepatocellular carcinoma. Panminerva Med 2008, 50(3): 221-6.
28. Carr, B.I., Kanke, F., Wise, M., Satomura, S. Clinical evaluation of lens culinaris agglutinin-reactive alpha-fetoprotein and des-gammacarboxy prothrombin in histologically proven hepatocellular carcinoma in the United States. Dig Dis Sci 2007, 52(3): 776-82.
29. Gotoh, M., Nakatani, T., Masuda, T. et al. Prediction of invasive activities in hepatocellular carcinomas with special reference to alphafetoprotein and des-gamma-carboxyprothrombin. Jpn J Clin Oncol 2003, 33(10): 522-6. (Pubitemid 43115246)
30. Kaibori, M., Matsui, Y., Yanagida, H., Yokoigawa, N., Kwon, A.H., Kamiyama, Y. Positive status of alpha-fetoprotein and desgamma- carboxy prothrombin: important prognostic factor for recurrent hepatocellular carcinoma. World J Surg 2004, 28(7): 702-7. (Pubitemid 39097129)
31. Leerapun, A., Suravarapu, S.V., Bida, J.P. et al. The utility of Lens culinaris agglutinin-reactive alpha-fetoprotein in the diagnosis of hepatocellular carcinoma: evaluation in a United States referral population. Clin Gastroenterol Hepatol 2007, 5(3): 394-402; quiz 267.
32. Saffroy, R., Pham, P., Reffas, M., Takka, M., Lemoine, A., Debuire, B. New perspectives and strategy research biomarkers for hepatocellular carcinoma. Clin Chem Lab Med 2007, 45(9): 1169-79. (Pubitemid 47396274)
33. Murata, K., Sakamoto, A. Impairment of clathrin-mediated endocytosis via cytoskeletal change by epithelial to fibroblastoid conversion in HepG2 cells: a possible mechanism of desgamma- carboxy prothrombin production in hepatocellular carcinoma. Int J Oncol 2008, 33(6): 1149-55.
34. Murata, K., Suzuki, H., Okano, H., Oyamada, T., Yasuda, Y., Sakamoto, A. Cytoskeletal changes during epithelial-to-fibroblastoid conversion as a crucial mechanism of desgamma- carboxy prothrombin production in hepatocellular carcinoma. Int J Oncol 2009, 35(5): 1005-14.
35. Bruix, J., Sherman, M. Management of hepatocellular carcinoma. Hepatology 2005, 42(5): 1208-36. (Pubitemid 43112690)
36. Trevisani, F., De, N.S., Rapaccini, G. et al. Semiannual and annual surveillance of cirrhotic patients for hepatocellular carcinoma: effects on cancer stage and patient survival (Italian experience). Am J Gastroenterol 2002, 97(3): 734-44. (Pubitemid 34245906)
37. Zhang, B., Yang, B. Combined alpha fetoprotein testing and ultrasonography as a screening test for primary liver cancer. J Med Screen 1999, 6(2): 108-10. (Pubitemid 29320849)
38. Bolondi, L., Sofia, S., Siringo, S. et al. Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis. Gut 2001, 48(2): 251-9. (Pubitemid 32141852)
39. Collier, J., Sherman, M. Screening for hepatocellular carcinoma. Hepatology 1998, 27(1): 273-8.
40. Trevisani, F., D'Intino, P.E., Morselli-Labate, A.M. et al. Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. J Hepatol 2001, 34(4): 570-5. (Pubitemid 32328514)
41. Sherman, M., Peltekian, K.M., Lee, C. Screening for hepatocellular carcinoma in chronic carriers of hepatitis B virus: incidence and prevalence of hepatocellular carcinoma in a North American urban population. Hepatology 1995, 22(2): 432-8.
42. Trevisani, F., D'Intino, P.E., Caraceni, P. et al. Etiologic factors and clinical presentation of hepatocellular carcinoma. Differences between cirrhotic and noncirrhotic Italian patients. Cancer 1995, 75(9): 2220-32.
43. Bayati, N., Silverman, A.L., Gordon, S.C. Serum alpha-fetoprotein levels and liver histology in patients with chronic hepatitis C. Am J Gastroenterol 1998, 93(12): 2452-6. (Pubitemid 29018554)
44. Franca, A.V., Elias Junior, J., Lima, B.L., Martinelli, A.L., Carrilho, F.J. Diagnosis, staging and treatment of hepatocellular carcinoma. Braz J Med Biol Res 2004, 37(11): 1689-705.
45. Yuen, M.F., Lai, C.L. Serological markers of liver cancer. Best Pract Res Clin Gastroenterol 2005, 19(1): 91-9.
46. Semela, D., Dufour, J.F. Angiogenesis and hepatocellular carcinoma. J Hepatol 2004, 41(5): 864-80.
47. Nakamura, S., Nouso, K., Sakaguchi, K. et al. Sensitivity and specificity of des-gamma-carboxy prothrombin for diagnosis of patients with hepatocellular carcinomas varies according to tumor size. Am J Gastroenterol 2006, 101(9): 2038-43. (Pubitemid 44337629)
48. Baek, Y.H., Lee, J.H., Jang, J.S. et al. Diagnostic role and correlation with staging systems of PIVKA-II compared with AFP. Hepatogastroenterology 2009, 56(91-92): 763-7.
49. Lok, A.S., Sterling, R.K., Everhart, J.E. et al. Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology 2010, 138(2): 493-502.
50. Yamamoto, K., Imamura, H., Matsuyama, Y. et al. Significance of alpha-fetoprotein and desgamma- carboxy prothrombin in patients with hepatocellular carcinoma undergoing hepatectomy. Ann Surg Oncol 2009, 16(10): 2795-804.
51. Miyaaki, H., Nakashima, O., Kurogi, M., Eguchi, K., Kojiro, M. Lens culinaris agglutinin-reactive alpha-fetoprotein and protein induced by vitamin K absence II are potential indicators of a poor prognosis: a histopathological study of surgically resected hepatocellular carcinoma. J Gastroenterol 2007, 42(12): 962-8.
52. Hagiwara, S., Kudo, M., Kawasaki, T. et al. Prognostic factors for portal venous invasion in patients with hepatocellular carcinoma. J Gastroenterol 2006, 41(12): 1214-9. (Pubitemid 46487212)
53. Shirabe, K., Itoh, S., Yoshizumi, T., Soejima, Y., Taketomi, A., Aishima, S., Maehara, Y. The predictors of microvascular invasion in candidates for liver transplantation with hepatocellular carcinoma-with special reference to the serum levels of des-gamma-carboxy prothrombin. J Surg Oncol 2007, 95(3): 235-40.
54. Sakon, M., Monden, M., Gotoh, M. et al. Relationship between pathologic prognostic factors and abnormal levels of des-gammacarboxy prothrombin and alpha-fetoprotein in hepatocellular carcinoma. Am J Surg 1992, 163(2): 251-6. (Pubitemid 23059267)
55. Grazi, G.L., Mazziotti, A., Legnani, C. et al. The role of tumor markers in the diagnosis of hepatocellular carcinoma, with special reference to the des-gamma-carboxy prothrombin. Liver Transpl Surg 1995, 1(4): 249-55.
56. Suehiro, T., Matsumata, T., Itasaka, H., Taketomi, A., Yamamoto, K., Sugimachi, K. Des-gamma-carboxy prothrombin and proliferative activity of hepatocellular carcinoma. Surgery 1995, 117(6): 682-91.
57. Sugimoto, H., Takeda, S., Inoue, S., Kaneko, T., Watanabe, K., Nakao, A. Des-gamma-carboxy prothrombin (DCP) ratio, a novel parameter measured by monoclonal antibodies MU-3 and 19B7, as a new prognostic indicator for hepatocellular carcinoma. Liver Int 2003, 23(1): 38-44. (Pubitemid 37265773)
58. Shimada, M., Yonemura, Y., Ijichi, H. et al. Living donor liver transplantation for hepatocellular carcinoma: a special reference to a preoperative des-gamma-carboxy prothrombin value. Transplant Proc 2005, 37(2): 1177-9. (Pubitemid 40590828)
59. Nanashima, A., Morino, S., Yamaguchi, H. et al. Modified CLIP using PIVKA-II for evaluating prognosis after hepatectomy for hepatocellular carcinoma. Eur J Surg Oncol 2003, 29(9): 735-42. (Pubitemid 37483946)
60. Shimada, M., Takenaka, K., Fujiwara, Y. et al. Des-gamma-carboxy prothrombin and alphafetoprotein positive status as a new prognostic indicator after hepatic resection for hepatocellular carcinoma. Cancer 1996, 78(10): 2094-100. (Pubitemid 26367601)
61. Imamura, H., Matsuyama, Y., Miyagawa, Y. et al. Prognostic significance of anatomical resection and des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma. Br J Surg 1999, 86(8): 1032-8. (Pubitemid 29387069)
62. Utsunomiya, T., Shimada, M., Shirabe, K., Kajiyama, K., Gion, T., Takenaka, K., Sugimachi, K. Clinicopathological characteristics of patients with extrahepatic recurrence following a hepatectomy for hepatocellular carcinoma. Hepatogastroenterology 2001, 48(40): 1088-93. (Pubitemid 32757751)
63. Kawakita, T., Shiraki, K., Yamanaka, Y. et al. A new prognostic scoring system involving desgamma- carboxy prothrombin as a useful marker for predicting prognosis in patients with hepatocellular carcinoma. Int J Oncol 2003, 23(4): 1115-20.
64. Omagari, K., Honda, S., Kadokawa, Y. et al. Preliminary analysis of a newly proposed prognostic scoring system (SLiDe score) for hepatocellular carcinoma. J Gastroenterol Hepatol 2004, 19(7): 805-11. (Pubitemid 38981404)
65. Toyoda, H., Kumada, T., Osaki, Y., Oka, H., Urano, F., Kudo, M., Matsunaga, T. Staging hepatocellular carcinoma by a novel scoring system (BALAD score) based on serum markers. Clin Gastroenterol Hepatol 2006, 4(12): 1528-36. (Pubitemid 44895414)
66. Maeda, S., Fujiyama, S., Tanaka, M., Ashihara, H., Hirata, R., Tomita, K. Survival and local recurrence rates of hepatocellular carcinoma patients treated by transarterial chemolipiodolization with and without embolization. Hepatol Res 2002, 23(3): 202-10. (Pubitemid 36104399)
67. Chan, C.Y., Lee, S.D., Wu, J.C. et al. The diagnostic value of the assay of des-gamma-carboxy prothrombin in the detection of small hepatocellular carcinoma. J Hepatol 1991, 13(1): 21-4.
68. Kasahara, A., Hayashi, N., Fusamoto, H. et al. Clinical evaluation of plasma des-gamma-carboxy prothrombin as a marker protein of hepatocellular carcinoma in patients with tumors of various sizes. Dig Dis Sci 1993, 38(12): 2170-6. (Pubitemid 24035747)
69. Nomura, F., Ishijima, M., Kuwa, K., Tanaka, N., Nakai, T., Ohnishi, K. Serum des-gamma-carboxy prothrombin levels determined by a new generation of sensitive immunoassays in patients with small-sized hepatocellular carcinoma. Am J Gastroenterol 1999, 94(3): 650-4. (Pubitemid 29124861)
70. Okuda, H., Nakanishi, T., Takatsu, K. et al. Serum levels of des-gamma-carboxy prothrombin measured using the revised enzyme immunoassay kit with increased sensitivity in relation to clinicopathologic features of solitary hepatocellular carcinoma. Cancer 2000, 88(3): 544-9. (Pubitemid 30056927)
71. Ando, E., Tanaka, M., Yamashita, F. et al. Diagnostic clues for recurrent hepatocellular carcinoma: comparison of tumour markers and imaging studies. Eur J Gastroenterol Hepatol 2003, 15(6): 641-8. (Pubitemid 36688229)
72. Ikoma, J., Kaito, M., Ishihara, T. et al. Early diagnosis of hepatocellular carcinoma using a sensitive assay for serum des-gamma-carboxy prothrombin: a prospective study. Hepatogastroenterology 2002, 49(43): 235-8. (Pubitemid 34289526)
73. Sassa, T., Kumada, T., Nakano, S., Uematsu, T. Clinical utility of simultaneous measurement of serum high-sensitivity des-gamma-carboxy prothrombin and Lens culinaris agglutinin Areactive alpha-fetoprotein in patients with small hepatocellular carcinoma. Eur J Gastroenterol Hepatol 1999, 11(12): 1387-92. (Pubitemid 30009344)
74. Shimauchi, Y., Tanaka, M., Kuromatsu, R. et al. A simultaneous monitoring of Lens culinaris agglutinin A-reactive alpha-fetoprotein and des-gamma-carboxy prothrombin as an early diagnosis of hepatocellular carcinoma in the follow-up of cirrhotic patients. Oncol Rep 2000, 7(2): 249-56.
75. Toyoda, H., Kumada, T., Kiriyama, S. et al. Prognostic significance of simultaneous measurement of three tumor markers in patients with hepatocellular carcinoma. Clin Gastroenterol Hepatol 2006, 4(1): 111-7. (Pubitemid 43129532)
76. Mita, Y., Aoyagi, Y., Yanagi, M., Suda, T., Suzuki, Y., Asakura, H. The usefulness of determining des-gamma-carboxy prothrombin by sensitive enzyme immunoassay in the early diagnosis of patients with hepatocellular carcinoma. Cancer 1998, 82(9): 1643-8. (Pubitemid 28208912)
77. Hakamada, K., Kimura, N., Miura, T. et al. Des-gamma-carboxy prothrombin as an important prognostic indicator in patients with small hepatocellular carcinoma. World J Gastroenterol 2008, 14(9): 1370-7. (Pubitemid 351425216)
78. Mazzaferro, V., Regalia, E., Doci, R. et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996, 334(11): 693-9. (Pubitemid 26079803)
79. Koike, Y., Shiratori, Y., Sato, S. et al. Desgamma- carboxy prothrombin as a useful predisposing factor for the development of portal venous invasion in patients with hepatocellular carcinoma: a prospective analysis of 227 patients. Cancer 2001, 91(3): 561-9. (Pubitemid 32105702)
80. Toyoda, H., Kumada, T., Kaneoka, Y. et al. Prognostic value of pretreatment levels of tumor markers for hepatocellular carcinoma on survival after curative treatment of patients with HCC. J Hepatol 2008, 49(2): 223-32.
81. Takahashi, S., Kudo, M., Chung, H. et al. PIVKA-II is the best prognostic predictor in patients with hepatocellular carcinoma after radiofrequency ablation therapy. Oncology 2008, 75 Suppl 1: 91-8.
82. Kim do, Y., Choi, M.S., Lee, J.H. et al. Milan criteria are useful predictors for favorable outcomes in hepatocellular carcinoma patients undergoing liver transplantation after transarterial chemoembolization. World J Gastroenterol 2006, 12(43): 6992-7.
83. Kobayashi, M., Ikeda, K., Kawamura, Y. et al. High serum des-gamma-carboxy prothrombin level predicts poor prognosis after radiofrequency ablation of hepatocellular carcinoma. Cancer 2009, 115(3): 571-80.
84. Taketomi, A., Sanefuji, K., Soejima, Y. et al. Impact of des-gamma-carboxy prothrombin and tumor size on the recurrence of hepatocellular carcinoma after living donor liver transplantation. Transplantation 2009, 87(4): 531-7.
85. Fujiki, M., Takada, Y., Ogura, Y., Oike, F., Kaido, T., Teramukai, S., Uemoto, S. Significance of des-gamma-carboxy prothrombin in selection criteria for living donor liver transplantation for hepatocellular carcinoma. Am J Transplant 2009, 9(10): 2362-71.
86. Harino, Y., Fujii, M., Imura, S., Morine, Y., Ikemoto, T., Soejima, Y., Shimada, M. The role of des-gamma-carboxyprothrombin expression in hepatocellular carcinoma. Hepatogastroenterology 2008, 55(85): 1385-9.
87. Yano, Y., Yamashita, F., Kuwaki, K. et al. Clinical features of hepatitis C virus-related hepatocellular carcinoma and their association with alpha-fetoprotein and protein induced by vitamin K absence or antagonist-II. Liver Int 2006, 26(7): 789-95. (Pubitemid 44165246)
88. Kim, H.S., Park, J.W., Jang, J.S. et al. Prognostic values of alpha-fetoprotein and protein induced by vitamin K absence or antagonist-II in hepatitis B virus-related hepatocellular carcinoma: a prospective study. J Clin Gastroenterol 2009, 43(5): 482-8.
89. Gao, F.J., Cui, S.X., Chen, M.H. et al. Desgamma-carboxy prothrombin increases the expression of angiogenic factors in human hepatocellular carcinoma cells. Life Sci 2008, 83(23-24): 815-20.
90. Wang, S.B., Cheng, Y.N., Cui, S.X. et al. Desgamma-carboxy prothrombin stimulates human vascular endothelial cell growth and migration. Clin Exp Metastasis 2009, 26(5): 469-77.
91. Kitai, S., Kudo, M., Minami, Y. et al. A new prognostic staging system for hepatocellular carcinoma: value of the biomarker combined Japan integrated staging score. Intervirology 2008, 51 Suppl 1: 86-94. (Pubitemid 351821847)
92. Kitai, S., Kudo, M., Minami, Y. et al. Validation of a new prognostic staging system for hepatocellular carcinoma: a comparison of the biomarker- combined Japan Integrated Staging Score, the conventional Japan Integrated Staging Score and the BALAD Score. Oncology 2008, 75 Suppl 1: 83-90.
93. Sterling, R.K., Jeffers, L., Gordon, F. et al. Utility of Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein and des-gamma-carboxy prothrombin, alone or in combination, as biomarkers for hepatocellular carcinoma. Clin Gastroenterol Hepatol 2009, 7(1): 104-13.
94. Seong, J., Shim, S.J., Lee, I.J., Han, K.H., Chon, C.Y., Ahn, S.H. Evaluation of the prognostic value of Okuda, Cancer of the Liver Italian Program, and Japan Integrated Staging systems for hepatocellular carcinoma patients undergoing radiotherapy. Int J Radiat Oncol Biol Phys 2007, 67(4): 1037-42.
95. Nanashima, A., Omagari, K., Sumida, Y. et al. Evaluation of new prognostic staging systems (SLiDe score) for hepatocellular carcinoma patients who underwent hepatectomy. Hepato-gastroenterology 2009, 56(93): 1137-40.